CTOs on the Move

AccuraGen Holdings

www.accuragen.com

 
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.accuragen.com
  • 1455 Adams Dr Suite 1015
    Menlo Park, CA USA 94025
  • Phone: 650.618.5028

Executives

Name Title Contact Details

Funding

AccuraGen Holdings raised $40M on 06/01/2016

Similar Companies

Noramco

Noramco, Inc. is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peplin Limited(Now LeoPharma)

Peplin Limited(Now LeoPharma) is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talon Therapeutics

Talon Therapeutics, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cogent Biosciences

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.